$-0.03 EPS Expected for Enzo Biochem, Inc. (ENZ), Acelrx Pharmaceuticals (ACRX) Shorts Decreased By 3.32%

May 17, 2017 - By Dolores Ford

Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) had a decrease of 3.32% in short interest. ACRX’s SI was 3.73 million shares in May as released by FINRA. Its down 3.32% from 3.86 million shares previously. With 187,200 avg volume, 20 days are for Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX)’s short sellers to cover ACRX’s short positions. The SI to Acelrx Pharmaceuticals Incorporated’s float is 13.99%. About 82,973 shares traded. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.

Analysts expect Enzo Biochem, Inc. (NYSE:ENZ) to report $-0.03 EPS on June, 14.They anticipate $0.01 EPS change or 25.00% from last quarter’s $-0.04 EPS. After having $-0.02 EPS previously, Enzo Biochem, Inc.’s analysts see 50.00% EPS growth. About 45,038 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.

AcelRx Pharmaceuticals, Inc. is a pharmaceutical firm focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The company has market cap of $108.00 million. The Firm operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. It currently has negative earnings. The Company’s lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03.

Among 5 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AcelRx Pharmaceuticals had 11 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Hold” on Tuesday, August 4. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, September 2. Seaport Global upgraded the shares of ACRX in report on Friday, May 6 to “Buy” rating. The firm has “Buy” rating by Jefferies given on Friday, October 30. TH Capital maintained the shares of ACRX in report on Monday, October 5 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 3 report. The stock of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has “Buy” rating given on Thursday, September 15 by TH Capital. Roth Capital maintained AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) rating on Monday, October 5. Roth Capital has “Buy” rating and $10.50 target.

Investors sentiment increased to 2.06 in Q4 2016. Its up 0.84, from 1.22 in 2016Q3. It improved, as 2 investors sold AcelRx Pharmaceuticals Inc shares while 16 reduced holdings. 15 funds opened positions while 22 raised stakes. 14.54 million shares or 6.63% less from 15.57 million shares in 2016Q3 were reported. 613,231 are held by Granahan Inv Mgmt Incorporated Ma. Raymond James Assocs invested in 0% or 45,000 shares. Joel Isaacson & Communications Ltd Liability Company reported 80,660 shares or 0.04% of all its holdings. 31,567 were accumulated by Rhumbline Advisers. Barclays Public Ltd holds 0% or 636 shares. Credit Suisse Ag holds 0% or 17,892 shares. Blackrock Fund Advisors accumulated 1.11 million shares. Utd Services Automobile Association owns 114,240 shares. Da Davidson holds 0% or 33,500 shares. Vanguard Gp holds 0% or 1.52 million shares in its portfolio. State Common Retirement Fund holds 0% or 23,475 shares in its portfolio. Blackrock Advsrs Ltd Liability Co reported 18,264 shares or 0% of all its holdings. Guggenheim Limited Liability Company owns 10,580 shares. Ing Groep Nv holds 0% or 13,000 shares. Natl Bank Of Montreal Can invested 0% of its portfolio in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX).

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce services and products. The company has market cap of $419.38 million. The Company’s divisions include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. It has a 13.53 P/E ratio. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Investors sentiment increased to 1.29 in 2016 Q4. Its up 0.05, from 1.24 in 2016Q3. It improved, as 9 investors sold Enzo Biochem, Inc. shares while 29 reduced holdings. 13 funds opened positions while 36 raised stakes. 23.43 million shares or 0.05% more from 23.42 million shares in 2016Q3 were reported. State Street reported 567,070 shares. Parametric Assoc Ltd Llc owns 0% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 51,334 shares. Citigroup Incorporated holds 40,895 shares or 0% of its portfolio. Kempner Cap Mgmt holds 70,001 shares or 0.35% of its portfolio. Pennsylvania-based Hudock Capital Group Lc has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Globeflex Capital L P has invested 0.39% in Enzo Biochem, Inc. (NYSE:ENZ). Bnp Paribas Arbitrage has 554 shares for 0% of their portfolio. Strs Ohio has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Blackrock Invest Mgmt Limited has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Tci Wealth Advsr has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ) for 498 shares. 22,822 are owned by Amer Int Grp. City Hldgs Company reported 120 shares stake. Kopp Advisors Ltd owns 211,974 shares for 1.55% of their portfolio. Voya Inv Management Ltd owns 22,377 shares. Fuller Thaler Asset Inc invested in 0% or 9,300 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: